Skip to main content

CORRECTION article

Front. Oncol., 11 May 2023
Sec. Genitourinary Oncology

YiHeng Du&#x;YiHeng Du1†WenHao Miao&#x;WenHao Miao2†Xiang JiangXiang Jiang3Jin CaoJin Cao3Bo WangBo Wang1Yi WangYi Wang1Jiang YuJiang Yu1XiZhi WangXiZhi Wang1HaiTao Liu*HaiTao Liu2*
  • 1Department of Urology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, China
  • 2Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
  • 3Department of Pathology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, China

Error in Author List and Author Contributions

In the published article, there was an error in the author list, and author WenHao Miao was not listed as co-first author with equal contribution to YiHeng Du. The corrected author list appears below.

YiHeng Du, 1, † WenHao Miao, 2, † Xiang Jiang, 3 Jin Cao, 3 Bo Wang, 1 Yi Wang, 1 Jiang Yu, 1 XiZhi Wang, 1 and HaiTao Liu 2*

The Author Contributions statement has also been updated to reflect this correction. The corrected Author Contributions statement appears below.

DY and MW have equal contributions to the manuscript. DY and LH designed the study. DY and MW conducted the statistical analysis and draft of the manuscript. JX and CJ did the immunohistochemistry analysis. WY and YJ made the relevant edits to the manuscript and figures. WX and LH revised the manuscript. All authors contributed to the article and approved the submitted version.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: bladder cancer, calumenin, tumor microenvironment, immunotherapy, gene mutation, ferroptosis

Citation: Du Y, Miao W, Jiang X, Cao J, Wang B, Wang Y, Yu J, Wang X and Liu H (2023) Corrigendum: The epithelial to mesenchymal transition related gene calumenin is an adverse prognostic factor of bladder cancer correlated with tumor microenvironment remodeling, gene mutation, and ferroptosis. Front. Oncol. 13:1185029. doi: 10.3389/fonc.2023.1185029

Received: 13 March 2023; Accepted: 25 April 2023;
Published: 11 May 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Du, Miao, Jiang, Cao, Wang, Wang, Yu, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: HaiTao Liu, aGFpdGFvLmxpdUBzaGdoLmNu

These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.